Company Overview
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -30.86% |
| 6 Months: | -30.07% |
| 3 Months: | -25.30% |
| 1 Month: | -10.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 47.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BNTC Benitec Biopharma Inc. R2KPHARMA | 8.65 | -8.83 | $301.74M | 0.00% | -42.71% | -33.21% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.00K | 77.00K | 28.00K | 55.00K | 1.00K | 1.00K | 0 | 25.00K | 48.00K | 0 | 14.00K | 54.00K | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 |
| Operating Income | -1.17M | -2.11M | -2.11M | -2.69M | -3.26M | -3.79M | -4.82M | -4.83M | -3.46M | -4.58M | -5.61M | -4.34M | -5.87M | -6.93M | -4.14M | -5.79M | -10.80M | -15.34M | -9.83M | -9.80M | -13.38M | -13.58M |
| Net Income | -1.15M | -2.09M | -2.10M | -2.72M | -3.25M | -3.91M | -5.04M | -4.82M | -3.27M | -5.09M | -5.41M | -4.40M | -5.95M | -6.80M | -4.28M | -5.06M | -9.55M | -14.50M | -8.80M | -8.96M | -11.84M | -11.94M |
| Diluted EPS | - | - | - | - | - | - | -0.62 | -0.59 | -0.40 | -7.98 | -3.34 | -2.67 | -3.05 | -2.64 | -0.23 | -0.18 | -0.26 | -0.38 | -0.21 | -0.22 | -0.26 | -0.24 |
| R&D Expense | 423.00K | 599.00K | 805.00K | 774.00K | 1.17M | 2.76M | 2.78M | 3.15M | 2.17M | 2.66M | 3.76M | 3.17M | 4.43M | 5.10M | 2.57M | 3.58M | 5.38M | 6.50M | 2.87M | 3.37M | 5.83M | 6.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 12.20M | 102.00K | 59.00K | 73.00K | 75.00K | 0 | - |
| Operating Income | 2.58M | -8.28M | -13.60M | -17.85M | -19.08M | -22.49M | -41.77M |
| Net Income | 2.61M | -8.27M | -13.88M | -18.21M | -19.56M | -21.75M | -37.92M |
| Diluted EPS | - | - | -3.23 | -37.88 | -14.12 | -1.22 | -1.05 |
| R&D Expense | 4.57M | 3.00M | 7.02M | 11.27M | 12.77M | 15.61M | 18.33M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 19.23M | 11.59M | 21.38M | 5.97M | 4.46M | 52.21M | 99.59M |
| Total Equity | 13.84M | 16.59M | 10.24M | 20.01M | 2.88M | 202.00K | 47.25M | 97.30M |
| Cash & Equivalents | 11.88M | 15.72M | 9.80M | 19.77M | 4.06M | 2.48M | 50.87M | 97.74M |
| Total Liabilities | - | 2.64M | 1.35M | 1.37M | 3.09M | 4.26M | 4.96M | 2.30M |
| Current Liabilities | - | 2.64M | 1.14M | 1.37M | 2.53M | 3.98M | 4.92M | 1.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.79M | -7.54M | -12.83M | -15.90M | -18.01M | -19.40M | -23.59M |
| Investing Cash Flow | -400.00K | -94.00K | -221.00K | -13.00K | -1.00K | -179.00K | -18.00K |
| Financing Cash Flow | - | 1.77M | 22.52M | 0 | 16.02M | 68.03M | 70.48M |
| Capital Expenditure | -404.00K | -95.00K | -221.00K | -13.00K | -1.00K | -179.00K | -18.00K |
| Free Cash Flow | 4.39M | -7.63M | -13.05M | -15.91M | -18.01M | -19.58M | -23.61M |
| Net Change in Cash | - | - | - | -15.91M | -2.00M | 48.45M | 46.88M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | 21.2% | -8,118.6% | -23,044.1% | -24,457.5% | -25,441.3% | - | - |
| Net Margin % | 21.4% | -8,111.8% | -23,528.8% | -24,942.5% | -26,082.7% | - | - |
| ROE % | 15.7% | -80.8% | -69.4% | -631.8% | -9,684.2% | -46.0% | -39.0% |
| ROCE % | 15.6% | -79.2% | -67.9% | -518.9% | -3,926.1% | -47.6% | -42.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Montanova Capital LLC | 33.11% | 11.55M | $102.43M |
| 2 | Jupiter Topco LLC | 7.11% | 2.48M | $21.98M |
| 3 | Franklin Resources, Inc. | 6.92% | 2.41M | $21.40M |
| 4 | Adage Capital Partners GP L.L.C. | 6.08% | 2.12M | $18.81M |
| 5 | RA Capital Management, L.P. | 5.30% | 1.85M | $16.41M |
| 6 | Nantahala Capital Management, LLC | 4.27% | 1.49M | $13.20M |
| 7 | Blackrock Inc. | 4.03% | 1.41M | $12.48M |
| 8 | Simplify Asset Management, Inc. | 2.88% | 1.01M | $8.92M |
| 9 | Vanguard Capital Management LLC | 2.74% | 954.53K | $8.47M |
| 10 | Infinitum Asset Management, LLC | 2.65% | 923.01K | $8.19M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BNTC
Benitec Biopharma Inc. Estimates – NASDAQ:BNTC - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFBBcDV6RlgyU1J3WVB2Mm5pbkVqeTF1RUR0SGJrWXViRjlxQ0paaVU0Ul83TnBoLXQ1NzdrNVRXTl9zYU9ONjlqbDBOTTNycExJZ2I1NWJ3NVhEZFVoZXBrakdpYWZjdGFUZ0NRQnNRTzV2MFRJU3lNRQ?oc=5" target="_blank">Benit…
BNTC Apr 2027 22.500 call (BNTC270416C00022500) stock price, news, quote and history - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE0yT2M0SlhvMjMtdVZYWlBNTF9ZaGMyazlQc3ZDcEdvQ0lrSTJ6VUJXNEtoUnlPODRlMk9VZVFiVFpUOXlRR0loZnlWbkk2ZlJkV01wT01oUGlTakdzTjlLQUJVRUY5QQ?oc=5" target="_blank">BNTC Apr 2027 22.500 call (BN…
Three board seats and an advisory pay vote face Benitec Biopharma (BNTC) holders on December 3. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPVDhvV3JBVFMwSlo2ZWk2SlBMSS1TTkdiYUJsVDBqQU43X1Nrb3E3UEdTSFRxZmh1QUw0VWs4bnlEaXVtM0VaeG0yMnJnUzB4d09VM293eFBJS2c5MzR2djN0UXZjbWJOMjJobVF3WVZIYV93LVBUQzJNcEVSU09pcG9yTWFvU0VsRjI1a1…
This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
<a href="https://news.google.com/rss/articles/CBMigwJBVV95cUxPRk05NDJ1Tlh3bmM4UlVCNXM5NzhzOFp2ZkZqZnZrbkVfR0NYUzR3SHJtSkk5S2VmUjZ6N0pacWtWbzNwemllaGtuWkZMUTFDeUU5NWE2c3E3R0N4T2J2RmhVWkx5RVRSSDhxMFFtdWhUcXV3UFNlNG5sR2g0UXpyWWVBaDhjZldTd1VJMl…
BNTC Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFAzTUF6c2pHQjhyTDMwOEdzRGp3WlJ6N21CNnYzM3RpY2lvYzFyR0tFUUtmQklfWDRKamVGNTJpVHN2eUR1VVN2TkVKTTNPbFJqUmxveHAwbG9xY2l4S3JBeTBTc3FHX3U4YmlsQUFRTmphTEJEQWpkRVZB?oc=5" target="_blank">BNT…
BENITEC BIOPHARMA Q4 2026 Earnings Preview: Recent $BNTC Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQRUs2aEY5YmVHNjFuMDZqMzgtcEZCUnBHdndwaW55N1Vjb2lMZThUSkM4a1hQOXJXUmxtZUl6YS1XNDhvVGttVmtMVnItdTg0LXR0Y0F1NmowVDZYQUVfYUM1WTZSeF9JM2JyYloyV0ZCb3hnM04xMTl4VGF1bFkwLU1IOUZKbVdFaDk4SE…
BNTC — Frequently Asked Questions
What is the current share price of Benitec Biopharma Inc. (BNTC)?
As of 2026-10-23 16:27 PDT, Benitec Biopharma Inc. (BNTC) trades at $8.65 on NasdaqCM. Its 52-week range is $8.11 to $16.52.
What is the market capitalisation of BNTC?
Benitec Biopharma Inc. (BNTC) has a market capitalisation of $301.74M on NasdaqCM.
What is the P/E ratio of BNTC?
BNTC trades at a trailing price-to-earnings (P/E) ratio of -8.83. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.72.
What is the return on equity (ROE) of BNTC?
BNTC has a return on equity (ROE) of -33.21%. Its return on capital employed (ROCE) is -42.71%.
Is BNTC a good stock to buy?
This page provides a data-driven analysis of Benitec Biopharma Inc. (BNTC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.